Cosma S.A., a Polish leader in the development of medicinal products basing on Cannabis Sativa, and SOMAÍ Pharmaceuticals, a fully vertically integrated international medical cannabis operator (MCO), are excited to announce a strategic partnership.
Background of the partnership
Cosma is now the Marketing Authorization Holder for innovative cannabis products under the SOMAÍ brand and core formulations under the Cosma brand as part of this partnership. Cosma and SOMAÍ will collaborate to present a variety of advanced cannabis product lines, such as inhalation extracts and oral solutions, to the Polish market. The novel oral solutions come from full-spectrum, pure cannabis extracts. Three distinct lines — Essentials, Origins, and Senses — will offer the oral and inhalation extracts.
In Poland, single-strain products — which are made from extracts of a single cannabis variety — are subject to stringent registration procedures that guarantee the greatest levels of efficacy and quality.
Future of the contract
Cosma extract coming from SOMAÍ should complete registration by the end of the year. In addition to that, several new products might go through registration, with the first ones available to patients by the end of 2025. Cosma S.A. will use its experience to negotiate the complex regulatory landscape and guarantee products’ entry to the market.
“We anticipate significant growth in our registrations—we plan to introduce up to 45 new products in the coming years in collaboration with SOMAÍ”
This is what Przemysław Lahuta, CEO of Cosma S.A. said.
“Our objective is to become the leader in the cannabis industry in Central and Eastern Europe. Our partnership shows true commitment to provide Polish patients and the medical community with cutting-edge, premium pharmaceuticals. We are keeping up the Cosma brand development and expanding the distribution of SOMAÍ’s new items in accordance with our strategic objectives.”
Michael Sassano is a CEO and founder of SOMAÍ Pharmaceuticals. He states that through this partnership, SOMAÍ focuses on improving Polish patients’ access to high-quality, innovative solutions that offer better performance and taste, with the potential to improve their lives. SOMAÍ has the largest range of extracted innovative products, with over 100 EU-GMP stabilized products. The company looks forward to introducing Polish doctors and patients to more advanced therapies and choices that will benefit them.”